CGRP(8-37) | H89 | KT-5720 | AM(22-52) | l-NOARG | KT-5823 | l-NOARG + AM(22-52) | KT-5823 + AM(22-52) | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
h | |||||||||||
Preproendothelin-1 mRNA (% control) | |||||||||||
6 | 50 ± 5* | 41 ± 8* | 56 ± 8* | 90 ± 13 | 91 ± 10 | 100 ± 10 | 95 ± 10 | 89 ± 10 | |||
12 | 40 ± 8* | 46 ± 6* | 51 ± 6* | 109 ± 10 | 110 ± 14 | 93 ± 13 | 93 ± 11 | 109 ± 13 | |||
ECE activity (ng ET-1/mg protein/h) | |||||||||||
6 | 183 ± 17 | 185 ± 20 | 173 ± 19 | 190 ± 25 | 183 ± 15 | 188 ± 25 | 177 ± 17 | 163 ± 19 | |||
12 | 166 ± 20 | 179 ± 23 | 182 ± 22 | 151 ± 28 | 186 ± 20 | 166 ± 21 | 180 ± 20 | 172 ± 22 | |||
Maximal no. of ETB sites (fmol/mg protein) | |||||||||||
6 | 350 ± 35* | 350 ± 35* | 350 ± 35* | 170 ± 14 | 179 ± 17 | 163 ± 18 | 180 ± 19 | 159 ± 15 | |||
12 | 375 ± 37* | 375 ± 37* | 375 ± 37* | 179 ± 16 | 189 ± 20 | 160 ± 15 | 179 ± 18 | 169 ± 16 |